HC Wainwright Increases Omeros (NASDAQ:OMER) Price Target to $40.00

Omeros (NASDAQ:OMER) had its target price upped by investment analysts at HC Wainwright from $20.00 to $40.00 in a research report issued on Thursday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 220.26% from the company’s current price. HC Wainwright also issued estimates for Omeros’ Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.52) EPS and FY2030 earnings at $6.69 EPS.

Several other brokerages have also weighed in on OMER. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 price target on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Wednesday, December 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $12.49 on Thursday. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The stock’s 50-day simple moving average is $10.58 and its 200-day simple moving average is $6.64. The firm has a market cap of $885.54 million, a price-to-earnings ratio of -6.18 and a beta of 2.38.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, research analysts predict that Omeros will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Omeros by 1.9% in the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock valued at $13,723,000 after buying an additional 63,381 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Omeros by 15.1% in the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after acquiring an additional 97,224 shares during the period. Bank of Montreal Can lifted its position in Omeros by 1.4% in the 2nd quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company’s stock valued at $1,713,000 after purchasing an additional 8,000 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

More Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.